Key facts
- Culmination’s last known valuation is $55.0M (Nov 2023).
- It has raised $10.0M; the latest was Secondary Transaction - Private in Jul 2025.
- Notable investors include EPIC Ventures, MSD Global Health Innovation Fund, Amgen Ventures, Intermountain Healthcare.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Culmination
- ·The full record, as it builds
Funding rounds
No funding rounds for Culmination are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Culmination
Operator of a clinical intelligence platform intended to accelerate the discovery and development of diagnostics and therapeutics. The company's platform leverages a de-identified patient data repository, enabling researchers to analyze vast datasets and identify novel clinical insights, expediting the development of life-saving treatments.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2022
- Employees
- 29
- Website
- culmination.com/
- Ownership
- Privately Held (backing)
Culmination doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Culmination shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Culmination in its N-PORT filings yet. We sweep new filings monthly.